Some Research on Pregnant and Postpartum Women with HIV Is Presented at CROI, But More Trials Are Needed
Pregnant people who are living with or vulnerable to HIV need to be included in clinical trials in order to close our knowledge gaps.
A CROI 2020 roundup of studies on birth control and women living with HIV.
Treating newborns with antiretroviral therapy in the hours after birth may help put HIV into remission.
Although injectable cabotegravir/rilpivirine is still yet to be approved by the FDA, evidence keeps mounting on the effectiveness of the shot for HIV treatment.
Researchers are happy but cautious, because this isn’t a strategy for most people with HIV.
Re-entry planning can help prevent opioid overdose and enable people living with HIV to connect with and stay in care.
Transgender people face discrimination in many facets of life. When it comes to discrimination in clinical settings, it can affect their health for the worse.
A systematic review of research between 2000 and 2016 found no studies of interventions specifically designed to support medication adherence among HIV-positive black women.
Taking more than five medications could be a problem. And many people with HIV are at risk of being on medication overload.
New analysis of the LATTE trial shows the two drugs cabotegravir and rilpivirine may also work as a daily oral formulation, which could be a bridge therapy for people who miss an injectable appointment.